Prosecution Insights
Last updated: October 04, 2026
Application No. 17/928,468

ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A

Final Rejection §102
Filed
Nov 29, 2022
Priority
May 29, 2020 — provisional 63/032,330 +1 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sanford Burnham Prebys Medical Discovery Institute
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
879 granted / 1237 resolved
+11.1% vs TC avg
Minimal +0% lift
Without
With
+0.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
97 currently pending
Career history
1309
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.2%
-22.8% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1237 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment and Rebuttal Arguments 2. The amendments to the claims filed on June 22, 2026 have been fully considered. The amendments are sufficient to overcome the 35 USC 102 rejection over RN 1058398-86-9. This ground of rejection is withdrawn. 3. Applicants’ rebuttal arguments for the obviousness-type double patenting rejection have been fully considered and are noted. However, the obviousness-type double patenting rejection is maintained because the present claims remain rejected. 4. Pursuant MPEP 803.02 the search and examination was extended. Prior art was found that anticipates the amended Markush claims. Therefore, the claims were rejected and claims to nonelected species were held withdrawn from further consideration. The amended Markush claims were further searched to the extent of the species shown below. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 5. Claim(s) 46,52, 59 and 63 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2371169-68-3 ( PNG media_image1.png 242 464 media_image1.png Greyscale ). The reference has a date of September 1, 2019 which antedates the present claims having an effective filing date of May 28, 2021 and priority claim to provisional application dated May 29, 2020. The compound corresponds to the present claims in the following manner: X1=S; R1=#3; R2=R3=R5=R6=H; R4=halo; m=0; R7=CO(Rb1=alkyl). 6. Claim(s) 46, 49 and 52 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2347459-81-6 ( PNG media_image2.png 200 492 media_image2.png Greyscale ). The reference has a date of June 27, 2019 which antedates the present claims having an effective filing date of May 28, 2021 and priority claim to provisional application dated May 29, 2020. The compound corresponds to the present claims in the following manner: X1=S; R1=#2; R2=R3=R5=H; R4=R6=halo; n=0; R7=CO(Rb1=alkyl). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Nov 29, 2022
Application Filed
Feb 02, 2026
Non-Final Rejection mailed — §102
Jun 22, 2026
Response Filed
Sep 01, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746246
COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
5y 0m to grant Granted Sep 29, 2026
Patent 12735424
FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
2y 5m to grant Granted Sep 15, 2026
Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
Patent 12674026
PROCESS FOR PREPARING POLYOL-BASED ESTERS OF ACYL-CAPPED HYDROXY CARBOXYLIC ACIDS
4y 6m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.3%)
2y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1237 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month